ライフサイエンスコーパス: median survival time

1 ting brain tumor with poor prognosis and low median survival time.

2 nd 10-year survival probability and estimate median survival time.

3 d 10-year survival probability and estimated median survival time.

4 nt high-dose cisplatin lavage had a 26-month median survival time.

5 ction was associated with a 5.5% increase in median survival time.

6 he Kaplan-Meier method to estimate patients' median survival time.

7 hallenge, ZWC more than doubles the animals' median survival time.

8 , as measured by bioluminescent imaging, and median survival time.

9 , respectively, and significant increases in median survival time.

10 9) from 40% to 46% and a 2-month increase in median survival time (1-3).

11 nd light chain-only (LCO) patients had worse median survival times (1.9 years) than patients with IgA

12 h LIG4 rs7325927 (V) had the worst survival (median survival time, 1.2 years) and exhibited the highe

13 onged but not indefinite allograft survival (median survival time 116 days).

14 exacerbated in C57BL/6-Kit(W-sh/W-sh) mice (median survival time = 13 vs 60 days in wild-type [WT] m

15 CMV retinitis was associated with mortality (median survival time, 13.6 vs. 29.7 months; P=.007).CONC

16 ients ultimately develop gradual graft loss (median survival time = 140 d), suggesting that alloreact

17 /- CD4+ T cells acutely rejected allografts (median survival time 15 days), whereas recipients recons

18 days), limited weight loss (<5%), and longer median survival times (~18 days) that were significantly

19 postoperative administration of LTbetaR-Ig (median survival time: 18 vs. >50 d, respectively, P=0.00

20 , fibrosis, and apoptosis; and prolonged the median survival time 2-fold in the myocyte-specific Lmna

21 nvasion and worse disease-specific survival (median survival time 20.3 versus 43.9 months, log-rank P

22 76% in patients who received other regimens (median survival time 223 days).

23 resulted in a significant improvement in the median survival time (24.5 days for saline, 26 days for

24 s 11% +/- 6% for vehicle-treated recipients (median survival time, 25 days) versus 63% +/- 12% for re

25 in patients diagnosed in more recent years (median survival time 3.3 years [95% CI 3.0-3.8] in 2001

26 iously reported IDEC-131-treated allografts, median survival time (35 +/- 31 days) was significantly

27 ared with patients without response (n = 61; median survival time, 35.6 months v not reached, respect

28 mice brain with significant increase in the median survival time (36 days) along with no toxicity.

29 /- 12% for recipients treated with WHI-P131 (median survival time, 36 days; P <.0001).

30 was markedly prolonged in BALB/c recipients (median survival time, 37 and 15 days, respectively; p <

31 cal follow-up showed a significantly shorter median survival time (4.1 y, age-adjusted hazard ratios

32 cinogenesis was lowest in the control group (median survival time, 40 weeks) and highest in the group

33 itial dendritic cells, are rejected acutely (median survival time 5 days).

34 dendritic cells (DC), are rejected acutely (median survival time 5 days).

35 NA levels and CD4(+) T-cell losses and died (median survival time, 5.5 weeks).

36 for patients with a single brain metastasis (median survival time 6.5 vs 4.9 months, p=0.0393).

37 he two arms of the study with respect to the median survival time (6.3 months for the gemcitabine plu

38 with better-than-expected survival (14-month median survival time; 61% 1-year, 32% 2-year, and 30% pr

39 pathCR or pathPR had a significantly longer median survival time (63.9 months) than those achieving

40 eceiving hemodynamic support alone survived (median survival times 65 vs 85 hours, respectively; P =

41 .9%) compared with etoposide plus cisplatin (median survival time, 7.6 months; 1-year survival rate,

42 97440 (V) and HMGA2 rs1563834 (V) genotypes (median survival time, 7.8 years).

43 Ten-year OS estimates (43% v 34%) and median survival times (8.7 v 7.3 years) favored ADT and

44 blockade in addition to lethal irradiation (median survival time, 81 days) when compared to mice tha

45 was 65% overall, 48% in the BDex+AA cohort (median survival time 821 days), and 76% in patients who

46 ion (4.1 v 4.6 months), or overall survival (median survival time, 9.3 months v 10.2 months; P = .74)

47 erved with the combined paclitaxel regimens (median survival time, 9.9 months; 1-year survival rate,

48 Median survival time after diagnosis of t-MDS/t-AML was

49 The median survival time after HCC diagnosis for persons wit

50 Median survival time after study enrollment was greater

51 Median survival time after TAVI was 3.4 years (95% confi

52 The median survival time among men who experienced progressi

53 streactivation growth kinetics and prolonged median survival times among infected animals.

54 ast 8.2% of the subjects in this cohort, and median survival times among men with LOY were 5.5 years

55 Median survival times among patients with CR/PR, SD, or

56 With a minimum follow-up of 24 months, the median survival time and 1- and 2-year survival rates we

57 The overall response rate was 60%, with a median survival time and 1-year survival probability of

58 Response rate was the primary end point; median survival time and 1-year survival rate were secon

59 Median survival time and 1-year survival rates were 6.6

60 ediction was assessed by using difference in median survival time and area under the curve with time-

61 The median survival time and OS rate at 12 months for this r

62 ligonucleotides (Group 3) did not affect the median survival time and the 35-day survival rate as com

63 Median survival time and time to progression were 11.4 a

64 Median survival times and 2-year survival rates for pati

65 Median survival times and 2-year survival rates for pati

66 h R0, R1 (<1 mm), and R1 (direct) status the median survival times and 5-year survival rates were 41.

67 on in tumor progression, a 50.0% increase in median survival time, and a 26.6% increase in necrotic p

68 etween percent maximal cytoreduction and log median survival time, and this correlation remained sign

69 However, the median survival times are similar to those with single-a

70 r differentiation according to difference in median survival time between high- and low-risk groups (

71 The differences in median survival times between persons in the lower and u

72 The differences in median survival times between persons in the lower and u

73 atients with multiple myeloma, extending the median survival time by on average 20%.

74 The median survival times by GPA score and diagnosis were de

75 Predicted median survival time calculated according to the Helsink

76 The median survival time, censored to liver transplantation,

77 Single organ lung metastasis had longer median survival times compared to the other sites (lung

78 ference, the number needed to treat, and the median survival time difference.

79 M/DOX liposome-treated group had the longest median survival time, double that of the DOX liposome-tr

80 The median survival time estimate was 389 days (95% CI, 267

81 The median survival time for 33 patients was 33.7 months.

82 The median survival time for all 402 eligible patients was 9

83 Median survival time for all patients was 15 months, wit

84 an time to progression was 21 weeks, and the median survival time for all patients was 19.9 months.

85 Median survival time for all patients with +8 was 9.9 mo

86 In 81 patients, the median survival time for EGFR/FISH-negative patients was

87 Median survival time for low-risk, intermediate-risk, an

88 The median survival time for overweight (2.64 y; range: 0.23

89 The median survival time for patients with low social attach

90 The median survival time for patients with TS <or= 7.5 x 10(

91 In an exact-matched case analysis (n = 38), median survival time for RSR13 patients was 7.3 months v

92 The median survival time for the 27 AML patients randomly as

93 The median survival time for women with optimally debulked a

94 The median survival times for all patients, those with gliob

95 treated controls (P < 0.0001); corresponding median survival times for groups b, c, and d were 36 (P

96 Median survival times for patients in quartiles one, two

97 Median survival times for the standard and experimental

98 spholipase A(2) IVa) (Group 4) increased the median survival time from 6 to 35 days and the 35-day su

99 progressing neurodegenerative disease with a median survival time from diagnosis of 1.5-3 years.

100 The median survival time from the time of diagnosis is appro

101 survived at the study endpoint, leading to a median survival time greater than 83 days (at least 32%

102 se mice as compared to control counterparts (median survival time, >70 vs 9.5 days).

103 For participants in cohort 1, the median survival time had not been reached at 174 days, w

104 After the amendment to add bevacizumab, the median survival time has not yet been reached for FOLFIR

105 unistic illness (OI) diagnosed in 1984-1997, median survival time improved from 11 months for 1984 di

106 ART to 57% in the HAART era (P = .0006), and median survival time improved from 8.3 to 43.2 months (P

107 Among patients with stage-specific data, the median survival time improved from 84 months (95% CI, 81

108 ombination of CCX872 and anti-PD-1 prolonged median survival time in 005 GSC GBM-bearing mice.

109 es, resulting in significant improvements in median survival time in a B16-F10 melanoma model.

110 levant tissues and a significant increase in median survival time in a dose-dependent manner.

111 Median survival time in months varied by tumor type: met

112 amelteon or melatonin significantly improved median survival time in rats (sepsis/melatonin [0.1 mg/k

113 The median survival time in the FOLFOX plus SIRT group was 2

114 Median survival time in the intermediate-risk group was

115 Median survival time in the pemetrexed/cisplatin arm was

116 The median survival time in the phase II portion was 14 mont

117 ose-dependent therapeutic response, with the median survival time increasing from 68 d for the lowest

118 Therapy usually fails and the median survival time is < 6 months.

119 urvival after systemic therapy; the reported median survival time is 7 to 17 months.

120 The median survival time is 9-12 months, with neither chemot

121 PG) is a lethal pediatric brain cancer whose median survival time is under one year.

122 Observed median survival times, Kaplan-Meier survival curves, pro

123 e prognosis for these patients is poor, with median survival times measured in months.

124 The median survival time (MST) and 1-year survival rate was

125 arrow cells displayed a significantly longer median survival time (MST) compared with mice that recei

126 Median survival time (MST) for cisplatin/pemetrexed was

127 ct against host-type breast cancer cells, as median survival time (MST) increased from 25.6 +/- 2.6 (

128 R mice accepted K skin grafts with increased median survival time (MST) more than 169 days compared t

129 C3H donor corneal allograft survival, with a median survival time (MST) of 21 days.

130 esis of IFN-gamma and NOS2 mRNA, and with an median survival time (MST) of 258.5 d.

131 oside (E), and radiation (XRT) resulted in a median survival time (MST) of 26 months.

132 For thymectomized rats, the median survival time (MST) of limb allograft in non-trea

133 tment with MPA-loaded nanogels increased the median survival time (MST) of lupus-prone NZB/W F1 mice

134 Chemotherapy alone yields a median survival time (MST) of no more than 10 months and

135 Median survival time (MST) was 14.9 months; by stage, MS

136 Median survival time (MST) was 20.6 months (95% CI, 14.0

137 =2); when given at 25 mg/kg twice daily, the median survival time (MST) was 27 days (n=4).

138 The median survival time (MST) was 5.4 months for the efapro

139 with recipients infused with wild-type SPC (median survival time (MST): 38 vs. 92 days, P=0.02).

140 metB mutant were highly virulent, with mouse median survival times (MST) of 28.5 and 42 days, respect

141 al was assessed by clinical examination, and median survival times (MST) were calculated.

142 Donor-specific islet grafts were accepted (median survival time [MST] > 180 days, n=6), whereas all

143 on of CIITA greatly enhanced graft survival (median survival time [MST] 36 days) over the survival of

144 compared with treatment with vehicle alone (median survival time [MST] AR-C117977 treated 15; 19 and

145 nificantly delayed by CD8+ T-cell depletion (median survival time [MST], 35 days) when compared to un

146 tched animals that rejected skin in 11 days (median survival time [MST], n=6) and hearts in 35 days (

147 val to 19 days compared with untreated mice (median survival time [MST]=10 days).

148 therapeutic advances, which have doubled the median survival time, myeloma continues to be a mostly i

149 ases (LBDs; majority Parkinson disease [PD]; median survival time not reached).

150 with stable or progressive disease (n = 56; median survival time, not reached v 36 months, respectiv

151 e clinician better outcomes than the current median survival time of 1 year for patients with sclerod

152 hose with an SUVr of at least 2.5, who had a median survival time of 10.1 (95% CI: 2.4, 15.9; P = .00

153 <or= 4.9 x 10(-3) (40 of 50 patients) had a median survival time of 10.2 months, compared with 1.9 m

154 deaths from lung cancer were documented with median survival time of 10.3 months (interquartile range

155 interval, 71% of patients were alive, with a median survival time of 10.9 months.

156 glioblastoma with a penetrance of 92% and a median survival time of 105 d.

157 H-SRT was well tolerated and resulted in a median survival time of 11 months after H-SRT, independe

158 nths), 71.6% of patients were deceased, with median survival time of 11 months for those who died.

159 The median survival time of 12.5 months for patients who rec

160 aster than single-mutant littermates, with a median survival time of 136 days (versus 158 days in p53

161 the central nervous system associated with a median survival time of 15 months, even with aggressive

162 rimary end point was successfully met with a median survival time of 15.3 months.

163 ths, 55 patients (76%) have died, yielding a median survival time of 18.3 months (95% CI, 14.6 to 22.

164 ion of 8.7 months, response rate of 45%, and median survival time of 19.5 months were observed for FO

165 sepsis without any treatment (Group 1) had a median survival time of 2 days and a zero (0) percent su

166 9 to detect a 33% increase over the expected median survival time of 21 months (one-sided P = .025, l

167 r final cohort included 118 patients, with a median survival time of 21 months from the time of recur

168 5% maximal cytoreduction had a mean weighted median survival time of 22.7 months, whereas cohorts wit

169 tients with SUVr of less than 1.7, who had a median survival time of 23.1 months (95% confidence inte

170 rvival was noted in CCR2-/- recipients, with median survival time of 24 and 12 days for CCR2-/- and W

171 Survival analysis demonstrated a median survival time of 24 months (95% confidence interv

172 0), and 5-8 (n=17) unfavorable genotypes had median survival time of 24.2, 16.4, 14.4, 9.6, and 7.4 m

173 Patients with 0 to 1 abnormality had a median survival time of 25 months (n = 26; 95% CI, 13-46

174 (+) T cells and rejected their grafts with a median survival time of 27 days.

175 al pneumonia, is a fatal lung disease with a median survival time of 3-5 years.

176 neuromuscular degenerative disorders, with a median survival time of 3-5 years.

177 eceived a salvage autotransplantation; their median survival time of 30 months was only slightly bett

178 5% maximal cytoreduction had a mean weighted median survival time of 33.9 months--an increase of 50%.

179 med severe multi-organ GVHD and died after a median survival time of 37 days.

180 peritoneal (IP) chemotherapy have reported a median survival time of 49 to 63 months and 2-year survi

181 In contrast, the poor-risk group had a median survival time of 5 months.

182 (35%) died over the follow-up period, with a median survival time of 5.6 years.

183 is with antibiotic treatment (Group 2) had a median survival time of 6 days and a 35-day survival rat

184 oma, a rapidly progressing malignancy with a median survival time of 6 to 9 months, have previously r

185 leading cause of cancer-related death with a median survival time of 6-12 months.

186 Although D2 skin grafts were rejected with a median survival time of 63.8 days in B10.A mice given AL

187 n follow-up time of 53 months, the actuarial median survival time of all eligible patients was 38.5 m

188 Median survival time of all registered patients was 9 mo

189 astoma is a universally lethal cancer with a median survival time of approximately 15 months.

190 These loci resulted in a reduction of median survival time of at least eight and five months i

191 fibrinogen-coated oil droplets improved the median survival time of B16F10 melanoma-bearing mice fro

192 10-30 mg/kg/day significantly increased the median survival time of BN heart allografts from 7 to 18

193 The median survival time of breast cancer patients with brai

194 d those who receive standard regimens have a median survival time of less than 1 year.

195 ection followed by radiotherapy (RT), with a median survival time of less than 10 months.

196 available for patients with DIPG, who have a median survival time of less than one year.

197 e growth of T24 xenografts and increases the median survival time of nude mice.

198 The median survival time of patients with GBM is under 10 mo

199 carcinomas revealed a striking reduction in median survival time of patients with high beta6 express

200 prevalence of idiopathic pulmonary fibrosis, median survival time of patients, and potential risk fac

201 Median survival time of rats bearing orthotopic glioma w

202 ll registered patients was 9 months, and the median survival time of resected patients was 13 months.

203 and breast cancer xenografts and doubled the median survival time of TCL1-Tg:p53(-/-) mice, which dev

204 mg/kg intraperitoneally, tid) prolonged the median survival time of the BMT recipients to 56 days.

205 The median survival time of the entire cohort was 9.2 months

206 ions, were used to assess the effects on log median survival time of the proportion of each cohort un

207 The median survival time of the SPCTNFRIIFc mice was 142 day

208 e liver and adrenal glands and increased the median survival time of the tumor-bearing mice.

209 toma (GBM) is an astrocytic brain tumor with median survival times of <15 months, primarily as a resu

210 ; 95.34% CI, 0.713 to 0.937; P = .0032) with median survival times of 13.50 versus 12.06 months, resp

211 rolonged allograft survival (P=0.0007), with median survival times of 14.5 days for Neoral alone, 7 d

212 CNSL face a particularly poor prognosis with median survival times of 2-12 months despite aggressive

213 e, two, or three or more at-risk alleles had median survival times of 27.5, 14.4, and 9.9 months, res

214 with those without diabetes (P < .001), with median survival times of 3 months for long-term diabetic

215 five, and six to seven adverse genotypes had median survival times of 36.2, 23.9, 16.3, 13.0, and 8.3

216 Median survival times of 393 v 98 days for a positive ve

217 ontrol antibody, anti-PD-1, or anti-OX40 had median survival times of 50 days or less, whereas mice g

218 Median survival times of 6 months for the ITT and 8.3 mo

219 s, with the highly significant difference in median survival times of 68 and >216 months, respectivel

220 with those without diabetes (P = .02), with median survival times of 9 months for long-term diabetic

221 and also have a poor prognosis with reported median survival times of less than 6 months.

222 elderly patients have remained dismal, with median survival times of only a few months.

223 ound an overall survival trend favoring TEM; median survival times of patients treated with DTIC and

224 was corresponding to a 7.8-month decrease in median survival time (P = 9.5 x 10(-14)).

225 estimated the time ratio (relative change in median survival time) per 100 working level months (rado

226 it remains uniformly incurable with a dismal median survival time post-treatment of 3-4 years.

227 nd initial respiratory impairment, and had a median survival time similar to bulbar onset patients.

228 treating early-stage micrometastases, giving median survival times similar to those obtained with ant

229 than 25% MCM2 immunoreactivity had a longer median survival time than patients with > or = 25% MCM2

230 Animals that received FUS+DOX (N=8) had a median survival time that was increased significantly (P

231 ss (>10%) than the unvaccinated controls and median survival times that were not significantly differ

232 Treatment with (a) increased median survival time to 34 days compared with 29 days fo

233 d antibody-conjugated liposome (b) increased median survival time to 38 days (P = 0.0002 relative to

234 tment with 120 muCi (213)Bi-7.16.4 increased median survival time to 41 days compared with 28 days fo

235 limus but not by CsA at the equivalent dose (median survival time: untreated, 6 days; tacrolimus, 18

236 classical predisposing host factors, and the median survival time was <4 months after diagnosis.

237 The median survival time was 10.9 months (95% CI, 7.8 to 14.

238 low-up of 28.5 months (for living patients), median survival time was 11.8 months (95% CI, 7.4 to 19.

239 In these 194 patients, the median survival time was 12.5 months (95% CI, 9.1 to 15.

240 The median survival time was 1257 days.

241 The overall median survival time was 131 d (95% confidence interval,

242 The median survival time was 14 months, and the 1- and 2-yea

243 The median survival time was 14 months.

244 after a diagnosis of esophageal cancer, the median survival time was 14.9 months (IQR, 7.1-52.3 mo)

245 Median survival time was 145 days as opposed to 78 days,

246 Median survival time was 15 months for the FISH-positive

247 a median follow-up time of 38.7 months, the median survival time was 15.8 months.

248 low-, intermediate-, and high-dose arms, the median survival time was 16, 14, and 13 months, respecti

249 The median survival time was 16.3 (11.47-22.57) months, and

250 The median survival time was 19.2, 14.7, and 13.2 months for

251 edian time to progression was 4.9 weeks, and median survival time was 19.7 weeks.

252 Median survival time was 20.0 months (95% CI, 5.0 to 43.

253 Median time to progression was 3 months, and median survival time was 20.2 months.

254 The median survival time was 21 months (95% confidence inter

255 , with a median follow-up time of 27 months, median survival time was 23 months for gefitinib (n = 11

256 The median survival time was 24.7 months.

257 The median survival time was 257 days, but differed consider

258 Median survival time was 26 months.

259 The median survival time was 26 years from disease onset.

260 signed to receive Sr-89 and doxorubicin, the median survival time was 27.7 months (4.9-37.7), and for

261 The median survival time was 28.7 months for patients in arm

262 years [SD 7.2], 54% female, 91% white), the median survival time was 3.8 years (95% CI 3.5-3.8).

263 Median survival time was 33.0 weeks for oral and 35.0 we

264 The median survival time was 35 months, and the most common

265 hs (range, 7.7 to >or= 42.0 months), and the median survival time was 35.8 months (range, 8.8 to >or=

266 Median survival time was 36 and 22 months for groups A a

267 The median survival time was 36 mo (range, 12-216 mo) from d

268 At a median follow-up time of 10 months, median survival time was 42 weeks (95% CI, 19.1 to 86.6

269 Median time to progression was 305 days, and median survival time was 451 days.

270 r, the 2-year survival rate was 91%, and the median survival time was 51 months.

271 Median survival time was 53.6 months for women with decr

272 Median survival time was 6.31 months for patients treate

273 The median survival time was 6.7 months for exatecan plus ge

274 Median survival time was 6.9 months.

275 ee survival was 2.9 months for each arm, and median survival time was 8.3 versus 7.9 months (P = not

276 Median survival time was 8.4 months (95% CI, 4.8 to 13.9

277 The median survival time was 8.6 months in the combination-t

278 s 2.3 months (95% CI, 2.1 to 2.6 months) and median survival time was 8.9 months (95% CI, 6.2 to 12.6

279 CEGT did not extend survival; the median survival time was 81.9 months (95% CI, 64.8 to 99

280 The median survival time was 82 days (interquartile range [I

281 Of 17 patients with known EGFR status, median survival time was 9.3 months for those with wild-

282 Results were considered promising if the median survival time was at least 21 months and of no fu

283 Median survival time was decreased in anti-CD54-treated

284 ficacy was greater in the MM model, in which median survival time was increased more than 4.5-fold.

285 ship between platinum dose-intensity and log median survival time was not statistically significant.

286 Median survival time was poorest in non-GBM patients wit

287 Median survival time was significantly prolonged in the

288 The response rate and median survival time were 20% and 8.2 months, respective

289 Median survival times were 111, 105, 125, and 167 days,

290 The median survival times were 17.6 months (95% CI, 16.1 to

291 Median survival times were 232 and 302 days, respectivel

292 The median time to progression and median survival times were 30 and 49 weeks for arm 1, 21

293 Median survival times were 6.3 months for IRINOGEM (95%

294 Median survival times were 6.5 and 9.7 months, respectiv

295 Median survival times were 6.7 months (95% CI, 5.8 to 7.

296 nths vs 8.4 months, respectively, P = .046), median survival times were not statistically different (

297 rated using L1210JF or KG-1 cells, increased median survival times were obtained with f-L-DOX treatme

298 to be detrimental because historical overall median survival times were similar to those of nonrespon

299 Retrospective analysis suggested prolonged median survival time with pertuzumab compared with histo

300 Median survival time without IRA failure was estimated a